Notification of Drug Policy Revisions Effective April 1, 2023 (posted February 1, 2023)
| Medical Drug Policy Name | Revised Criteria |
|---|---|
| Intravenous Iron Replacement Therapy | Removed Feraheme from the restricted product list. Restructured trial and failure requirements by age and added requirement of trial and failure of two products (i.e., Ferrlecit, Venofer, INFeD, Feraheme) for adults. Policy notification given 2/1/2023 for effective date 4/1/2023. |
Blue Cross and Blue Shield of North Carolina does not discriminate on the basis of race, color, national origin, sex, age or disability in its health programs and activities. Learn more about our non-discrimination policy and no-cost services available to you.
Information in other languages: Español 中文 Tiếng Việt 한국어 Français العَرَبِيَّة Hmoob ру́сский Tagalog ગુજરાતી ភាសាខ្មែរ Deutsch हिन्दी ລາວ 日本語
© 2024 Blue Cross and Blue Shield of North Carolina. ®, SM Marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross and Blue Shield Association.